In GI-Oncology, the progress of sophisticated treatment options like TKI or immunotherapy lags behind other malignant diseases like lung cancer, breast cancer or hematological diseases. Currently, there are interesting new data on tumor biology and “intelligent” treatment options. For example, there are new data on PARP-Inhibition in pancreatic cancer, BRAF inhibition in CRC, NTRK-targeting in patients, a wave of data on mutations in metastatic cholangiocellular carcinoma, immunotherapy for colorectal cancer and MSI tumors in general. Several new concepts like CMS are emerging and will possibly find its way into clinical routine within the next years. This progress, however, is derived either from complex data (f.e. CMS) or is limited to defined, small subgroups of patients, which makes the classification of these data, especially for clinical use, challenging.
Aim of this research topic is to describe the current hot-topics in GI-oncology and which value they have for (i) clinical use now and in the near future, (ii) understanding of disease biology and (iii) what we can expect from these for the future. Suggested topics, include, but not limited to the following:
• Immunotherapy in GI-Cancers: especially the link between molecular genetics and immunooncology
• Targeted treatment concepts: ranging from classical EGFR-inhibiton over new BRAF inhibition to newer FGFR-2-inhibition
• Molecular oncology: the role of molecular profiling in GI-oncology – are GI-cancers or subgroups (f.e. MSI) a more promising entity for this approach as other tumors?
• MSI: molecular basis and the link to immunosensitivity, is there an understanding of non immuno-responsive MSI tumors
• CMS: where do we stand and where do we go?
• BRCA/BRCAness in GI-cancers: ready for clinical use? Different from other “new mutations”, BRCAness is less defined but promising. Focus should be on BRCAness
• Targeted treatment concepts for known mutations: BRAF, NTRK, IDH1, FGFR2, BRCA ….
• Molecular profiling in GI-cancer: describing efficacy (CARIS, other platforms…) and compare to other entities (original article)
In GI-Oncology, the progress of sophisticated treatment options like TKI or immunotherapy lags behind other malignant diseases like lung cancer, breast cancer or hematological diseases. Currently, there are interesting new data on tumor biology and “intelligent” treatment options. For example, there are new data on PARP-Inhibition in pancreatic cancer, BRAF inhibition in CRC, NTRK-targeting in patients, a wave of data on mutations in metastatic cholangiocellular carcinoma, immunotherapy for colorectal cancer and MSI tumors in general. Several new concepts like CMS are emerging and will possibly find its way into clinical routine within the next years. This progress, however, is derived either from complex data (f.e. CMS) or is limited to defined, small subgroups of patients, which makes the classification of these data, especially for clinical use, challenging.
Aim of this research topic is to describe the current hot-topics in GI-oncology and which value they have for (i) clinical use now and in the near future, (ii) understanding of disease biology and (iii) what we can expect from these for the future. Suggested topics, include, but not limited to the following:
• Immunotherapy in GI-Cancers: especially the link between molecular genetics and immunooncology
• Targeted treatment concepts: ranging from classical EGFR-inhibiton over new BRAF inhibition to newer FGFR-2-inhibition
• Molecular oncology: the role of molecular profiling in GI-oncology – are GI-cancers or subgroups (f.e. MSI) a more promising entity for this approach as other tumors?
• MSI: molecular basis and the link to immunosensitivity, is there an understanding of non immuno-responsive MSI tumors
• CMS: where do we stand and where do we go?
• BRCA/BRCAness in GI-cancers: ready for clinical use? Different from other “new mutations”, BRCAness is less defined but promising. Focus should be on BRCAness
• Targeted treatment concepts for known mutations: BRAF, NTRK, IDH1, FGFR2, BRCA ….
• Molecular profiling in GI-cancer: describing efficacy (CARIS, other platforms…) and compare to other entities (original article)
